Pancreatic Cancer Research

ResearcherUniversity of FoggiaNo recent work listed

Cristina Jiménez‐Luna

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2395-1728; OpenAlex author ID A5013564078. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers

Papers 13

  1. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s415631↗
  2. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. Last author DOI 10.3390/metabo13070872↗
  3. Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Last author DOI 10.4251/wjgo.v15.i2.268↗
  4. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Co-author DOI 10.1016/j.biopha.2022.113669↗
  5. Liquid biopsy approach to pancreatic cancer. Co-author DOI 10.4251/wjgo.v13.i10.1263↗
  6. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. First author DOI 10.3390/cancers12041002↗
  7. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Co-author DOI 10.20892/j.issn.2095-3941.2019.0252↗
  8. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. First author DOI 10.1371/journal.pone.0194844↗
  9. Proteomic biomarkers in body fluids associated with pancreatic cancer. Co-author DOI 10.18632/oncotarget.24654↗
  10. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study. Co-author DOI 10.1177/1087057116671490↗
  11. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  12. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Co-author DOI 10.1097/mcg.0000000000000623↗
  13. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Co-author DOI 10.1007/s10620-014-3291-3↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jose Carlos Prados · 12 shared papers, 2014–2023 · strength 1.30
  2. Consolación Melguizo · 9 shared papers, 2014–2023 · strength 1.03
  3. Octavio Caba · 9 shared papers, 2014–2023 · strength 0.88
  4. Gloria Perazzoli · 4 shared papers, 2019–2023 · strength 0.66
  5. Joaquina Martínez-Galán · 4 shared papers, 2018–2023 · strength 0.58
  6. Raúl Ortíz · 5 shared papers, 2014–2023 · strength 0.53
  7. Carolina Torres · 6 shared papers, 2014–2021 · strength 0.47
  8. Francisco Quiñonero · 3 shared papers, 2019–2023 · strength 0.44
  9. Sonia Perales · 2 shared papers, 2014–2021 · strength 0.18
  10. José Pérez del Palacio · 2 shared papers, 2017–2020 · strength 0.18
  11. Antonio Irigoyen · 3 shared papers, 2014–2018 · strength 0.17
  12. Jose Manuel Sanchez-Manas · 1 shared paper, 2021 · strength 0.15
  13. Manuel Benavides · 2 shared papers, 2016–2018 · strength 0.13
  14. Javier Gallego-Plazas · 2 shared papers, 2016–2018 · strength 0.13
  15. Carmen Guillén‐Ponce · 2 shared papers, 2016–2018 · strength 0.13
  16. Enrique Aranda · 2 shared papers, 2016–2018 · strength 0.13
  17. Ariadna Martín-Blázquez · 1 shared paper, 2020 · strength 0.11
  18. Francisca Vicente · 1 shared paper, 2020 · strength 0.11
  19. Kevin Doello · 1 shared paper, 2019 · strength 0.10
  20. Sandra Ríos Peces · 1 shared paper, 2017 · strength 0.07
  21. Antonia Aránega · 1 shared paper, 2014 · strength 0.04
  22. Ana Linares · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.